KR20190027415A - An anti-wrinkle activity composition comprising swertiajaponin - Google Patents
An anti-wrinkle activity composition comprising swertiajaponin Download PDFInfo
- Publication number
- KR20190027415A KR20190027415A KR1020170114064A KR20170114064A KR20190027415A KR 20190027415 A KR20190027415 A KR 20190027415A KR 1020170114064 A KR1020170114064 A KR 1020170114064A KR 20170114064 A KR20170114064 A KR 20170114064A KR 20190027415 A KR20190027415 A KR 20190027415A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- active ingredient
- acceptable salt
- swertiajaponin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000000694 effects Effects 0.000 title claims abstract description 38
- DLVLXOYLQKCAME-DGHBBABESA-N 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one Chemical compound COC1=CC=2OC(C=3C=C(O)C(O)=CC=3)=CC(=O)C=2C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DLVLXOYLQKCAME-DGHBBABESA-N 0.000 title claims abstract description 20
- DLVLXOYLQKCAME-UHFFFAOYSA-N Swertiajaponin Natural products COC1=CC=2OC(C=3C=C(O)C(O)=CC=3)=CC(=O)C=2C(O)=C1C1OC(CO)C(O)C(O)C1O DLVLXOYLQKCAME-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 230000001153 anti-wrinkle effect Effects 0.000 title abstract description 3
- 230000037303 wrinkles Effects 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 23
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 22
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims description 16
- 235000013376 functional food Nutrition 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 230000000475 sunscreen effect Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- 235000013402 health food Nutrition 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 84
- 230000002401 inhibitory effect Effects 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 230000002000 scavenging effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- -1 3,4-dihydroxyphenyl Chemical group 0.000 description 11
- 230000032683 aging Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 206010051246 Photodermatosis Diseases 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000008845 photoaging Effects 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 4
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002849 elastaseinhibitory effect Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006400 oxidative hydrolysis reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 스워티아자포닌 (swertiajaponin) 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물에 관한 것으로, 구체적으로 스워티아자포닌 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 피부 외용제; 스워티아자포닌 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 건강기능식품; 스워티아자포닌 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선 또는 치료용 약학적 조성물; 및 스워티아자포닌 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선용 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles comprising swertiajaponin or an acceptable salt thereof as an active ingredient. More specifically, the present invention relates to a cosmetic composition for improving skin wrinkles comprising sweatyazonin or an acceptable salt thereof as an active ingredient, Improving external skin application agent; A health functional food for improving skin wrinkles comprising as an active ingredient soutathiazonin or a pharmaceutically acceptable salt thereof; A pharmaceutical composition for improving or treating skin wrinkles comprising, as an active ingredient, sulthiazaponin or a pharmaceutically acceptable salt thereof; And a quasi-drug composition for improving skin wrinkles, which comprises soutiazaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
피부는 신체의 외부를 덮고 있는 하나의 막으로 여러 가지 외부의 자극, 장해, 건조 등의 환경요소로부터 신체를 보호해 주는 다양한 생리적 기능을 수행하여 내부 장기와 그 밖의 체내 기관을 보호 조절하는 역할을 한다. 조직학적으로 피부를 수직으로 잘라 현미경으로 관찰하면 상피조직인 표피, 결체조직인 진피, 피하조직으로 이루어져 있고, 각각의 조직은 특이적 기능을 지니고 있으며 서로 상호적 관계를 갖는다.Skin is a membrane that covers the outside of the body. It plays a role of protecting and protecting internal organs and other body organs by performing various physiological functions to protect the body from environmental factors such as external stimuli, obstacles and drying do. Histologically, the skin is cut vertically and observed with a microscope. The epithelium is composed of the epidermis, the connective tissue, the dermis, and the subcutaneous tissue. Each tissue has a specific function and mutual relationship with each other.
그 중 결체조직은 주로 콜라겐과 엘라스틴으로 구성되어 있으며, 콜라겐은 피부 진피의 구조를 유지하는데 결정적인 역할을 한다. 피부의 진피층에 존재하는 콜라겐은 세포외 기질의 대부분을 차지하고 있으며, 피부의 기계적인 견고성 유지, 결합조직의 저항력 및 조직의 결합력 강화, 세포 접착의 지탱, 세포분할 및 분화의 유도 등이 알려져 있다. 콜라겐을 포함하여 진피의 세포외 기질을 구성하는 엘라스틴과 프로테오글리칸, 피브로넥틴, 라미닌 등과 같은 당 단백질은 대부분 섬유아세포에서 만들어져 세포 밖으로 내보내지며 모든 영양소와 대사 폐기물은 이 세포외 공간을 통해 운반되고 대사된다. 상기 당 단백질은 수많은 세포-표면 반응에 관여하며, 다량의 수분을 세포 외 기질에 보유하게 함으로써 피부에 탄력을 유지하고 주름을 방지하는 역할을 한다(Ko, J.H., Lee, S.J., and Lim, K.T., Toxicol. in Vitro, 19, 353, 2005; Cho, W.G., Kyung K.Y., and Yu, S.M., J. of the Korean Chemists, Soc., 26(2), 191, 2009).The connective tissue is mainly composed of collagen and elastin, and collagen plays a crucial role in maintaining the structure of the skin dermis. Collagen existing in the dermal layer of the skin occupies most of the extracellular matrix, and it is known that maintenance of mechanical rigidity of the skin, resistance of connective tissue and strengthening of tissue binding, support of cell adhesion, induction of cell division and differentiation are known. The elastin, proteoglycans, fibronectin, laminin, and other glycoproteins that make up the extracellular matrix of the dermis, including collagen, are mostly made out of fibroblasts and exported out of the cell. All nutrients and metabolic waste are transported and metabolized through the extracellular space. The glycoprotein is involved in numerous cell-surface reactions and retains a large amount of water in the extracellular matrix, thereby maintaining the elasticity of the skin and preventing wrinkles (Ko, JH, Lee, SJ, and Lim, KT , Toxicol. In Vitro, 19, 353, 2005; Cho, WG, Kyung KY, and Yu, SM, J. of the Korean Chemists, Soc., 26 (2), 191, 2009).
또한, 피부보습 정도는 화장품, 피부과학 및 의약품 등의 분야에서 중요한 요소로, 각질층의 보습상태는 피부의 외형(피부의 유연성 및 거친 정도)과 직접적으로 연관되어 있으며, 건강상태의 척도가 된다. 또한, 각질층의 피부 수분 함량은 피부의 컨디션 및 투과성과 관련되는 피부 막 항상성에 영향을 미치므로, 화장품 또는 바르는 의약품의 흡습도가 달라질 수 있어 피부 보습이 중요한 요소로 작용하고 있다(Esposito E, Drechsler M, Mariani P, Sivieri E, Bozzini R, Montesi L, Menegatti E, Cortesi R, Int J Cosmet Sci, 29, p 39-47, 2007; Kasting GB, Barai ND, J Pharm Sci, 92, p1624-31, 2003).In addition, the degree of skin moisturization is an important factor in the fields of cosmetics, dermatology and medicine, and the moisturizing condition of the stratum corneum is directly related to the appearance of the skin (flexibility and roughness of the skin) and is a measure of health condition. In addition, since the skin moisture content of the stratum corneum influences the skin membrane homeostasis related to the condition and permeability of the skin, the degree of hygroscopicity of the cosmetics or the medicine to be applied can be changed, thus skin moisturization is an important factor (Esposito E, Drechsler M, Mariani P, Sivieri E, Bozzini R, Montesi L, Menegatti E, Cortesi R, Int J Cosmet Sci 29, p 39-47, 2007; Kasting GB, Barai ND, J Pharm Sci 92, p 1624-31, 2003).
한편, 피부의 노화는 나이가 들어감에 따라 자연적으로 발생하는 내인성 노화(intrinsic aging 또는 자연노화)와 광노화(actinic aging)가 합쳐져 나타난다. 두 가지의 노화 사이에는, 주름이 생성되고 피부면역세포인 랑거한스 세포와 진피세포 성분이 줄어드는 등 공통점이 많이 있으나 광노화에서는 피부가 두꺼워지고 탄력섬유가 증가하는데 반하여 자연노화는 피부가 얇아지는 차이가 있다. 이러한 자연노화와 광노화가 복합적으로 작용하면 주름을 형성시키게 된다. 즉, 피부조직의 노화에 따라 진피층에 있는 섬유아세포(human skin fibroblast)가 노화되어 섬유질과 기질의 생성능력이 줄어들게 되며, 기질의 양이 전반적으로 감소하여 피부의 두께가 얇아지고 피부의 탄력을 저하시켜 주름이 형성되거나, 자외선 노출에 의하여 자유 라디칼(free radical)과 활성산소종(reactive oxygen species, ROS)의 생성으로 인해 피부를 촉촉하고 부드러우며 유연하게 탄력을 유지시키는 교원질과 섬유질을 공격하여 주름생성을 가속화한다. 한편, 많은 연구 결과 대부분의 피부 노화는 연령적인 자연노화보다는 햇빛에 의해 더 많이 진행된다는 사실이 밝혀졌다. 어떤 학자는 80% 이상의 주름은 햇빛에 의해 생긴다는 연구 결과를 발표한바 있다. Skin aging, on the other hand, is a combination of intrinsic aging (natural aging) and actinic aging that occurs naturally with age. Between the two aging, wrinkles are generated, and Langerhans cells, which are skin immune cells, and dermal cell components are reduced. However, in the photoaging, skin becomes thicker and elastic fibers increase, while natural aging becomes thinner have. This combination of natural aging and photoaging creates wrinkles. In other words, aging of the skin tissue causes aging of the human skin fibroblast in the dermal layer, resulting in a decrease in the ability of the fibrous material and the substrate to be formed. The overall amount of the substrate is reduced, thereby reducing the thickness of the skin, (Wrinkles) or wrinkles, collides with collagen and fiber that keeps skin supple, soft and supple due to the formation of free radicals and reactive oxygen species (ROS) Accelerate generation. On the other hand, many studies have shown that most skin aging is progressed more by sunlight than aging natural aging. Some scholars have reported that over 80% of wrinkles are caused by sunlight.
자외선에 만성적으로 노출될 때의 영향을 가장 상징적으로 보여주는 것이 농부나 어부들의 피부이다. 외관적으로 피부가 거칠고 깊은 주름이 있으며, 자외선에 노출되기 쉬운 목덜미 부분에서 특징적인 마름모꼴의 주름을 볼 수 있다. 이와 같은 변화를 자연적인 노화와 구별하여 광노화라고 하며, 이런 증상이 크게 나타나는 부위가 항상 햇빛에 노출되는 안면부위이다. It is the skin of farmers and fishermen that most symbolically shows the effect of chronic exposure to ultraviolet light. Apparently, the skin has rough and deep wrinkles, and wrinkles characteristic of the rhombus can be seen in the nape of the neck, which is easily exposed to ultraviolet rays. These changes are called photoaging, distinguishing them from natural aging, and the areas where these symptoms are most visible are always exposed to sunlight.
또한, 근래는 환경오염에 의해 지표상에 도달하는 자외선의 양이 증가하고 있으며, 레저 및 야외활동 등의 증가로 자외선에 노출될 가능성이 높아지고 있는 실정이다. 따라서, 광노화로 인해 피부가 거칠어지고 주름이 형성되는 것에 대한 케어가 더욱더 중요해지고 있다. In recent years, the amount of ultraviolet rays reaching the surface of the earth is increasing due to environmental pollution, and the possibility of exposure to ultraviolet rays is increasing due to an increase in leisure and outdoor activities. Therefore, care for skin roughness and wrinkle formation due to photoaging is becoming more and more important.
피부관리에 대한 관심이 폭발적으로 증가하고 있는 현 시점에서, 이러한 주름을 개선할 수 있는 화장품에 대한 요구 또한 절실한 실정이다. 특히, 주름을 개선하는 우수한 효과를 나타내면서도 안전성이 입증되어 소비자들이 거부감 없이 안심하고 사용할 수 있는 화장료를 비롯한 피부외용제가 요구되고 있다. At present, interest in skin care is increasing explosively, there is also a need for cosmetics that can improve such wrinkles. In particular, there is a demand for an external preparation for skin including a cosmetic composition that shows excellent effects of improving wrinkles and has safety and can be safely used by consumers without any feeling of resistance.
이에, 피부 주름 개선을 위하여 다양한 방법이 제안되고 있다. 예를 들어, 피부 노화에 대한 광범위한 연구가 발전되면서 피부 내에서의 콜라겐이 갖는 기능에 주목하여, 피부 주름을 개선하고자 콜라겐을 적용한 화장품들이 시판되고 있다. 그러나, 콜라겐을 배합한 화장품은 콜라겐을 피부 표면에 도포하는 것으로서, 고분자인 콜라겐이 경피 흡수되어 그 기능을 수행하기는 어려우므로, 주름 개선의 효과는 미미하다. Accordingly, various methods for improving skin wrinkles have been proposed. For example, as extensive research on skin aging has been developed, attention has been paid to the function of collagen in the skin, and cosmetics using collagen have been marketed to improve skin wrinkles. However, cosmetics containing collagen are applied to the surface of the skin, and collagen, which is a polymer, is percutaneously absorbed, and it is difficult to perform the function, so that the effect of improving wrinkles is insignificant.
또한, 콜라겐 합성 촉진물질로 기존에 retinoic acid, TGF(transforming growth factor, 발암증식인자: Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974), 동물 태반 유래의 단백질(JP8-231370), betulinic acid(JP8-208424), 클로렐라 추출물(JP9-40823, JP10-36283, 섬유아세포 증식 촉진작용) 등이 알려져 있으나, 피부에 적용시 자극과 발적 등의 안전성의 문제로 사용량이 제한이 있으며, 효과가 미미하여 실질적인 피부 기능 개선 효과를 기대하기 어려운 단점이 있다. 따라서, 피부에 적용시 생체에 안전하고 주름 개선 효과가 우수한 피부외용제의 개발이 필요한 실정이다. In addition, as collagen synthesis promoting substance, retinoic acid, TGF (transforming growth factor, carcinogenesis factor: Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974) However, when applied to the skin, the use amount is limited due to safety issues such as irritation and erythema. However, there is a problem in that the amount of betulinic acid (JP138139), betulinic acid (JP8-208424) and chlorella extract (JP9-40823, JP10-36283, fibroblast proliferation promoting action) And the effect is insignificant, so that it is difficult to expect substantial skin function improvement effect. Therefore, it is necessary to develop a skin external preparation which is safe to the living body when applied to the skin and has excellent wrinkle-reducing effect.
상기와 같은 배경 하에, 본 발명자들은 피부에 안전하고 주름 개선효과가 우수한 물질을 연구하던 중, 스워티아자포닌을 유효성분으로 포함하는 조성물이 활성산소 소거, 과산화 질산염 소거, 엘라스타제 저해, 인공피부 주름 저해 등을 규명함으로써, 이를 활용한 피부 주름 개선용 화장료 조성물, 피부 외용제, 건강기능식품 및 약학적 조성물을 확인함으로써 본 발명을 완성하였다.Under the above circumstances, the inventors of the present invention have been studying a substance which is safe for skin and has excellent wrinkle-reducing effect, and it has been found that a composition comprising soutiazaponin as an active ingredient is useful for the active oxygen scavenging, nitrate nitrate scavenging, Inhibition of skin wrinkles, and the like, thereby confirming the cosmetic composition for improving skin wrinkles, the external preparation for skin, the health functional food and the pharmaceutical composition, thereby completing the present invention.
본 발명의 하나의 목적은, 스워티아자포닌 (swertiajaponin) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공하는 것이다.One object of the present invention is to provide a cosmetic composition for improving skin wrinkles comprising swertiajaponin or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은, 스워티아자포닌 (swertiajaponin) 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 피부 외용제를 제공하는 것이다.It is still another object of the present invention to provide a skin external preparation for improving skin wrinkles comprising swertiajaponin or an acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은, 스워티아자포닌 (swertiajaponin) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 건강기능식품을 제공하는 것이다.It is still another object of the present invention to provide a health functional food for improving skin wrinkles containing swertia japonin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은, 스워티아자포닌 (swertiajaponin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선 또는 치료용 약학적 조성물을 제공하는 것이다.It is still another object of the present invention to provide a pharmaceutical composition for improving or treating skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은, 스워티아자포닌 (swertiajaponin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선용 의약외품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a quasi-drug composition for improving skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This will be described in detail as follows. On the other hand, each description and embodiment disclosed in the present invention can be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present invention fall within the scope of the present invention. Further, the scope of the present invention is not limited by the detailed description described below.
상기 목적을 달성하기 위한 하나의 양태로서, 본 발명은 스워티아자포닌 (swertiajaponin) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.In one aspect of the present invention, the present invention provides a cosmetic composition for improving skin wrinkles comprising swertiajaponin or a cosmetically acceptable salt thereof as an active ingredient.
본 발명에서 "스워티아자포닌"은 상기 화학식 1로 표시되고, 분자식 C22H22O11, 분자량 462.407 g/mol을 가지는 화합물로서, Leucanthoside, 또는 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one 으로도 명명된다. 상기 스워티아자포닌의 구체적인 약리활성에 대해서는 아직 연구가 진행 중이나, 직접적으로 피부 주름 개선 효과를 갖는지 여부에 대해서는 밝혀진 바가 없다.In the present invention, "sulthiazaponin" is a compound having the molecular formula C22H22O11 and the molecular weight of 462.407 g / mol, represented by the above formula (1), such as Leucanthoside or 2- (3,4-dihydroxyphenyl) -5-hydroxy- 6- (hydroxymethyl) oxan-2-yl] chromen-4-one. ≪ / RTI > Although the specific pharmacological activity of the above-mentioned sulthiazaponin is still being studied, it has not been known whether or not it has the effect of directly improving the wrinkles of the skin.
상기 스워티아자포닌의 획득 방법은 특별히 한정되지 않으며, 당업계에 공지된 방법을 이용하여 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다.The method for obtaining the sultiazaponin is not particularly limited, and may be chemically synthesized using a method known in the art, or a commercially available material may be used.
본 발명의 화학식 1로 표시되는 스워티아자포닌은 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 본 발명의 스워티아자포닌은 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.The sultiazaponins represented by Formula 1 of the present invention may exist in solvated as well as unsolvated forms. The sulthiazaponins of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.
본 발명에 있어서, "화장품학적으로 허용 가능한 염"은 스워티아자포닌이 다른 물질과 결합한 염의 형태인 것으로, 화장품학적으로 스워티아자포닌과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, the term "cosmetically acceptable salt" means a salt form in which sulthiazaponin is combined with other substances, and refers to a substance that can exhibit similar activities as sulthiazaponin cosmetically.
본 발명에 있어서, “피부 주름 개선”이라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In the present invention, " improvement of skin wrinkles " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명의 상기 화장료 조성물은 활성산소 소거, 과산화 질산염 소거, 엘라스타제 저해 또는 인공피부의 주름 저해 활성을 가질 수 있다.The cosmetic composition of the present invention may have active oxygen scavenging, nitric oxide scavenging, elastase inhibiting activity or wrinkle inhibiting activity of artificial skin.
본 발명의 일 실시예에서는, 피부 주름과 관련된 엘라스타제의 활성에 대한 스워티아자포닌의 억제 효과를 확인한 결과, 상기 화합물은 엘라스타제 활성 감소 효과를 나타내었는바, 스워티아자포닌을 포함하는 조성물은 피부 주름 개선용 화장료 조성물로 사용될 수 있음을 확인하였다(도 3).In one embodiment of the present invention, the inhibitory effect of sultiazaponin on the activity of elastase related to skin wrinkles was confirmed. As a result, the compound showed an effect of reducing elastase activity, Can be used as a cosmetic composition for improving skin wrinkles (Fig. 3).
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention can be used as a cosmetic composition in the form of a solution, an ointment for external use, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, an emulsion, a makeup base, But are not limited to, emulsions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays It is not.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a general skin cosmetic composition, and examples thereof include oil, water, a surfactant, a moisturizer, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulations.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil may be used, in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, .
본 발명의 다른 하나의 양태는, 스워티아자포닌 (swertiajaponin) 또는 이의 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선용 피부 외용제를 제공한다.Another aspect of the present invention provides an external skin preparation for skin wrinkles comprising swertiajaponin or an acceptable salt thereof as an active ingredient.
본 발명에 있어서, "스워티아자포닌"은 상기에서 설명한 바와 같다.In the present invention, "sultiazaponin" is as described above.
본 발명에 있어서, "허용 가능한 염"이란, 스워티아자포닌이 다른 물질과 결합한 염의 형태인 것으로, 스워티아자포닌과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, "acceptable salt" means a salt form in which sulthiazoponin binds to another substance, and means a substance capable of exhibiting an activity similar to sulthiazaponin.
본 발명의 용어 "피부 외용제"는 일반적으로 피부 외용에 사용하는 물질 전반을 포함하는 포괄하는 개념으로, 피부 외용제 제형의 비제한적인 예로는 경고제(PLASTERS), 로션제(LOTIONS), 리니멘트제(LINIMENTS), 액제(LIQUIDS AND SOLUTIONS), 에어로솔제(AEROSOLS), 엑스제(EXTRACTS), 연고제(OINTMENTS), 유동엑스제(FLUIDEXTRACTS), 유제(EMULSIONS), 현탁제(SUSPESIONS), 캅셀제(CAPSULES), 크림제(CREAMS), 연질, 경질 젤라틴 캅셀, 첩부제, 또는 서방화제제가 있다.The term "external preparation for skin" of the present invention is a generic concept including the entirety of materials used for external skin application. Non-limiting examples of external preparations for skin include PLASTERS, LOTIONS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS, SUSPENSIONS, CAPSULES, , Creams (CREAMS), soft, hard gelatin capsules, pastes, or sustained release preparations.
본 발명의 일 실시예에서는, 피부 주름과 관련된 엘라스타제의 활성에 대한 스워티아자포닌의 억제 효과를 확인한 결과, 상기 화합물은 엘라스타제 활성 감소 효과를 나타내었는바, 스워티아자포닌을 포함하는 조성물은 피부 주름 개선용 피부 외용제로 사용될 수 있음을 확인하였다(도 3).In one embodiment of the present invention, the inhibitory effect of sultiazaponin on the activity of elastase related to skin wrinkles was confirmed. As a result, the compound showed an effect of reducing elastase activity, Can be used as an external preparation for skin wrinkle improvement (Fig. 3).
본 발명에 따른 피부 외용제는 상용되는 무기 또는 유기의 담체, 부형제 및 희석제를 가하여 고체, 반고체 또는 액상의 형태로 제제화된 비경구 투여제일 수 있다. 상기 비경구 투여를 위한 제재로는 점적제, 연고, 로션, 겔, 크림, 패취, 스프레이, 현탁제 및 유제로 이루어진 군에서 선택되는 경피 투여형 제형일 수 있으나, 이에 제한되지 않는다.The external preparation for skin according to the present invention may be a parenteral dosage form which is formulated in solid, semi-solid or liquid form by adding a compatible inorganic or organic carrier, excipient and diluent. The preparation for parenteral administration may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions, and emulsions.
상기 외용제에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. Examples of the carrier, excipient and diluent which can be contained in the external preparation include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
각 제형에 의한 피부 외용제 조성물에 있어서, 상기한 본 발명의 조성물 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승효과가 일어날 수 있다.In the composition for external application for skin according to each formulation, components other than the composition of the present invention may be mixed and selected without difficulty by those skilled in the art depending on the formulation or use purpose of other external preparation for skin, etc. In this case, A synergistic effect can occur.
본 발명의 또 다른 하나의 양태는 스워티아자포닌 (swertiajaponin) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선용 건강기능식품을 제공한다.Another aspect of the present invention provides a health functional food for improving skin wrinkles comprising swertia japonin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에 있어서, "스워티아자포닌"은 상기에서 설명한 바와 같다.In the present invention, "sultiazaponin" is as described above.
본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 “기능성”이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 건강기능식품은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 주름 개선 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The health functional food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has advantages in that it does not have side effects that may occur when a food is used as a raw material for a long period of time, and has excellent portability. Can be ingested as an adjuvant to improve skin wrinkles.
본 발명의 일 실시예에서는, 피부 주름과 관련된 엘라스타제의 활성에 대한 스워티아자포닌의 억제 효과를 확인한 결과, 상기 화합물은 엘라스타제 활성 감소 효과를 나타내었는바, 스워티아자포닌을 포함하는 조성물은 피부 주름 개선용 건강기능식품으로 사용될 수 있음을 확인하였다(도 3).In one embodiment of the present invention, the inhibitory effect of sultiazaponin on the activity of elastase related to skin wrinkles was confirmed. As a result, the compound showed an effect of reducing elastase activity, Was used as a health functional food for improving skin wrinkles (FIG. 3).
본 발명의 건강기능식품은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau Martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
상기 외에 본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부 당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, A carbonating agent used in a carbonated beverage, and the like. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
본 발명의 다른 하나의 양태는 스워티아자포닌 (swertiajaponin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선 또는 치료용 약학적 조성물을 제공한다.Another aspect of the present invention provides a pharmaceutical composition for improving or treating skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 하나의 양태는 스워티아자포닌 (swertiajaponin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는, 피부 주름 개선용 의약외품 조성물을 제공한다.Another aspect of the present invention provides a quasi-drug composition for improving skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에 있어서, "스워티아자포닌"은 상기에서 설명한 바와 같다.In the present invention, "sultiazaponin" is as described above.
본 발명에 있어서, "약학적으로 허용 가능한 염"이란 스워티아자포닌이 다른 물질과 결합한 염의 형태인 것으로, 약학적으로 스워티아자포닌과 비슷한 활성을 나타낼 수 있는 물질을 의미한다.In the present invention, the term "pharmaceutically acceptable salt" means a salt form in which sulthiazaponin is combined with another substance, and means a substance which can exhibit an activity similar to sulthiazaponin pharmacologically.
본 발명의 일 실시예에서는, 피부 주름과 관련된 엘라스타제의 활성에 대한 스워티아자포닌의 억제 효과를 확인한 결과, 상기 화합물은 엘라스타제 활성 감소 효과를 나타내었는바, 스워티아자포닌을 포함하는 조성물은 피부 주름 개선 또는 치료용 약학적 조성물로 사용될 수 있음을 확인하였다(도 3).In one embodiment of the present invention, the inhibitory effect of sultiazaponin on the activity of elastase related to skin wrinkles was confirmed. As a result, the compound showed an effect of reducing elastase activity, Can be used as a pharmaceutical composition for improving or treating skin wrinkles (Fig. 3).
본 발명의 약학적 조성물은 피부 주름 생성을 예방하고 치료하기 위한 통상의 방법에 따라 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 에어로졸, 멸균 주사용액 등의 형태로 제형화가 가능하다.The pharmaceutical composition of the present invention may be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, aerosols, sterile injection solutions or the like in accordance with a conventional method for preventing and treating skin wrinkle formation . ≪ / RTI >
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 포함되며, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, . In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, Can be used.
비경구투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등을 포함할 수 있다. 비수성용제와 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일 등과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the non-aqueous solvent and the suspending agent include vegetable oils such as propylene glycol, polyethylene glycol and olive oil, injectable esters such as ethyl oleate, and the like.
또한, 본 발명의 약학적 조성물은 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 담체, 부형제 또는 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀루로오즈, 하이드록시 프로필 메틸 셀룰로오즈, 미정질 셀룰로오즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 플로필히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 이산화규소 등의 광물유 등이 사용될 수 있다.In addition, the pharmaceutical composition of the present invention may further comprise a carrier, an excipient or a diluent. Examples of the carrier, excipient or diluent include lactose, textol, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Mineral oil such as propyl methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and silicon dioxide can be used have.
본 발명에 따른 약학적 조성물의 구체적인 투여량은 제제화 방법, 환자의 상태 및 체중, 환자의 성별, 연령, 질병의 정도, 약물형태, 투여경로 및 기간, 배설 속도, 반응 감응성 등과 같은 요인들에 따라 당업자에 의해 다양하게 선택될 수 있으며, 투여량 및 횟수는 어떠한 면에서든 본 발명의 범위를 제한하는 것은 아니다.The specific dosage of the pharmaceutical composition according to the present invention depends on factors such as the formulation method, the patient's condition and body weight, the patient's sex, age, degree of disease, drug type, administration route and period, excretion rate, May be variously selected by those skilled in the art, and the dosage and the number of times do not limit the scope of the present invention in any way.
본 발명의 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로를 통해 투여될 수 있다. 투여의 모든 방식은 예상될 수 있으며, 예를 들어 경구, 정맥, 근육 또는 피하 주사에 의해 투여될 수 있다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like through various routes. All modes of administration may be expected and may be administered, for example, by oral, intravenous, intramuscular or subcutaneous injection.
본 발명의 스워티아자포닌을 유효성분으로 포함하는 조성물은 피부 주름과 관련된 엘라스타제 활성을 저해하며, 특히, 인공피부에서도 광노화에 의한 주름 생성을 효과적으로 저해하였으므로, 스워티아자포닌을 유효성분으로 포함하는 조성물은 피부 주름 개선용 화장료 조성물, 피부 주름 개선용 피부 외용제 또는 건강기능식품 등으로 유용하게 사용될 수 있다.Since the composition comprising the sultiazaponin of the present invention as an active ingredient inhibits the elastase activity associated with skin wrinkles and effectively inhibits wrinkle formation due to photoaging even in artificial skin, Can be usefully used as a cosmetic composition for improving skin wrinkles, a skin external preparation for improving skin wrinkles, or a health functional food.
도 1은 스워티아자포닌의 활성산소 (Reactive oxygen species, ROS) 소거 활성을 확인한 그래프이다; CON: 정상군, SIN-1: 3-morpholinosydnonimine hydrochloride 투여군(음성대조군), vitamin C: SIN-1 + 비타민 C 투여군(양성대조군), SJ: SIN-1 + 스워티아자포닌 투여군, ###p < 0.001 vs. CON, *p < 0.05, **p < 0.01, ***p < 0.001 vs. SIN-1
도 2는 스워티아자포닌의 과산화 질산염 (Peroxynitrite, ONOO-)소거 활성을 확인한 그래프이다; ###p < 0.001 vs. CON, ***p < 0.001 vs. SIN-1
도 3은 스워티아자포닌의 엘라스타제(elastase) 저해 효과를 확인한 그래프이다; vehicle: 무첨가군, con: 엘라스타제 + N-숙시닐-(Ala)3-ρ-나이트로아닐라이드(기질) 처리군, SJ_(1, 5, 10, 40, 80): 엘라스타제 + 기질 + 스워티아자포닌 (각각 1, 5, 10, 40, 80)μM 처리군, adenosine_50: 엘라스타제 + 기질 + 아데노신 50μM 처리군(양성대조군), *p < 0.05, ***p < 0.001 vs. con
도 4는 인공피부에서 스워티아자포닌의 주름 저해 활성을 확인한 그래프이다; vehicle: 정상군, UVB 50mJ/cm2: UVB 조사군, SJ (10, 20)μM: UVB 조사 + 스워티아자포닌 (각각 10, 20)μM 처리군1 is a graph showing the reactive oxygen species (ROS) scavenging activity of sulthiazaponin; CON: normal group, SIN-1: 3-morpholinosydnonimine hydrochloride administration group (negative control), vitamin C: SIN-1 + Vitamin C treated group (positive control), SJ: SIN-1 + seuwo thiazol Zaporozhye non-treated group, ### p <0.001 vs. CON, * p < 0.05, ** p < 0.01, *** p < SIN-1
2 is a graph showing the peroxynitrite (ONOO-) scavenging activity of sulthiazaponin; ### p <0.001 vs. CON, *** p < SIN-1
3 is a graph showing the inhibitory effect of sulthiazaponin on elastase; vehicle: no added group, con: elastase + N-succinyl- (Ala) 3-p-nitroanilide (substrate) treated group, SJ_ (1, 5, 10, 40, 80) substrate + seuwo thiazol Zaporozhye Nin (each of 1, 5, 10, 40, 80) μM treatment group, adenosine_50: elastase substrate + + 50μM adenosine-treated group (positive control group), * p <0.05, *** p <0.001 etc. con
4 is a graph showing wrinkle-inhibiting activity of sultiazaponin in artificial skin; vehicle: normal group,
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예Example 1: One: 스워티아자포닌의Of suotiazaponin 항산화 효과 확인 Identify antioxidant effect
1-1. 1-1. 스워티아자포닌의Of suotiazaponin 활성산소 (Reactive oxygen species, Reactive oxygen species, ROSROS ) 소거 활성 확인) Confirmation of scavenging activity
스워티아자포닌의 활성산소 소거 효과 측정은 종래의 논문 (Chem Res Toxicol. 5: 227-231, 1992)에 기재된 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) 분석법을 이용하였다.The measurement of the active oxygen scavenging effect of sulthiazaponin was carried out using the 2 ', 7'-dichlorodihydrofluorescein diacetate (DCFDA) assay described in a conventional paper (Chem Res. Toxicol. 5: 227-231, 1992).
구체적인 실험 방법으로서, 3차 증류수에 용해된 에스테라아제 (600U/ml)와 에탄올 (99.9%)에 용해된 DCFDA (12.5mM)를 -20℃에 stock solution으로 저장하였고, 실험에 사용 시, 6 U/ml 에스테라아제와 10mM DCFDA를 혼합하여 조제된 2',7'-dichlorodihydrofluorescein (DCFH) 용액을 22℃에서 20분간 배양한 후, 사용 전까지 암소에서 냉동 보관하였다.As a specific experimental method, Esterase (600 U / ml) dissolved in tertiary distilled water and DCFDA (12.5 mM) dissolved in ethanol (99.9%) were stored as stock solution at -20 ° C. 2 ', 7'-dichlorodihydrofluorescein (DCFH) solution prepared by mixing 10 μg / ml Escherichia coli and 10 mM DCFDA was incubated at 22 ° C for 20 minutes and then kept frozen in a cow until use.
이후, 지용성의 DCFDA가 에스테라아제 또는 산화적 가수 분해로 인해 비형광성인 DCFH로 탈아세틸화되며, DCFH는 활성산소에 의해 산화되어 강한 형광을 나타내는 DCF (2',7'-dichlorofluorescein)가 되므로, 여기 (excitation) 파장 485nm 및 이미션 (emission) 파장 535 nm에서 형광광도계 (GENios, TECAN)로 측정하였다. Then, the lipid soluble DCFDA is deacetylated with the non-fluorescent DCFH due to the esterase or the oxidative hydrolysis, and the DCFH is oxidized by the active oxygen to become DCF (2 ', 7'-dichlorofluorescein) showing strong fluorescence. (GENios, TECAN) at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
상기 혼합물에 스워티아자포닌을 농도별로 처리하여 에스터라아제 저해 활성을 확인하였으며, 활성산소 생성원으로는 SIN-1 (3-morpholinosydnonimine hydrochloride) 10μM을 이용하였고, 양성대조군은 강력한 활성산소 소거효과가 있는 비타민 C 처리군으로 하였다.The mixture was treated with sulthiazonin at different concentrations to confirm the activity of estrase inhibition. SIN-1 (3-morpholinosydnonimine hydrochloride) 10 μM was used as the source of the active oxygen, and the positive control had strong active oxygen scavenging effect Vitamin C treatment group.
실험 결과, 도 1에서 확인할 수 있는 바와 같이, 활성산소 생성원인 SIN-1 처리 후 활성산소가 급격히 증가하였으나, 상기 SIN-1과 스워티아자포닌 (50μM)을 함께 처리한 처리 군은 SIN-1 (10μM)만 처리된 대조군에 비해 활성산소 생성이 현저히 억제되었으며, 특히 양성대조군인 비타민 C (100μM) 처리군에 근접하게 활성산소 생성이 현저하게 억제됨을 확인하였다 (도 1). As a result, as shown in FIG. 1, active oxygen increased rapidly after treatment with SIN-1, which is a source of active oxygen, but treatment with SIN-1 and sutiathaponin (50 μM) (10 μM), the production of active oxygen was markedly inhibited, and the production of active oxygen was remarkably inhibited in the vicinity of the group treated with vitamin C (100 μM), which is a positive control (FIG. 1).
따라서, 스워티아자포닌은 우수한 활성산소 소거능이 있음을 확인하여, 항산화 물질로 유용하게 사용될 수 있음을 확인하였다.Therefore, it was confirmed that sulthiazaponin has excellent active oxygen scavenging ability and thus it can be used effectively as an antioxidant.
1-2. 1-2. 스워티아자포닌의Of suotiazaponin 과산화 질산염 ( Peroxide nitrate ( PeroxynitritePeroxynitrite , , ONOOONOO -- )소거 활성 확인) Confirmation of scavenging activity
스워티아자포닌의 ONOO- 소거효과는 종래 게재된 논문 (Kooy et al., Free Radic. Biol. Med. 16: 149-156, 1994)을 참고하여, ONOO-에 의해서 매개되는 디하이드로로다민123(dihydrorhodamine123, DHR123)의 산화반응을 이용하여 형광 분광분석법으로 측정하였다. The scavenging activity is prior published papers - ONOO of seuwo thiazol Zaporozhye Nin (Kooy et al, Free Radic Biol Med 16:.... 149-156, 1994) to refer to, ONOO - in-dihydro-rhodamine 123 is mediated by (dihydrorhodamine123, DHR123) by fluorescence spectroscopy.
비형광성 DHR123은 ONOO-에 의해서 산화되어 형광을 띄는 로다민123(Rhodamine123)을 생성하게 되는데, ONOO-를 유도하기 위해서 SIN-1 (10μM)을 이용하였고, 해당 혼합물에 스워티아자포닌을 농도별로 처리하여 형광 수준을 측정함으로서 과산화 질산염 소거 활성을 확인하였다. 양성대조군은 강력한 ONOO- 소거효과가 있는 비타민 C 처리 군으로 하였다.-Free light-DHR123 is ONOO - is oxidized by there is generated a striking fluorescent rhodamine 123 (Rhodamine123), ONOO - in order to induce was used to SIN-1 (10μM), by seuwo thiazol Zaporozhye Nin a concentration in the mixture And the fluorescence level was measured to confirm the nitric oxide scavenging activity. Positive control group was treated with vitamin C treatment with strong ONOO - elimination effect.
실험 결과, 도 2에서 확인할 수 있는 바와 같이, SIN-1에 의해서 ONOO-가 급격히 유도되었으나, 상기 SIN-1 과 스워티아자포닌 (50μM)을 함께 처리한 처리 군은 SIN-1만 처리된 대조군에 비해 ONOO- 생성이 현저히 억제되었으며, 특히 양성대조군인 비타민C (100μM) 처리 군보다 ONOO- 생성이 더욱 현저하게 억제됨을 확인하였다 (도 2). As shown in FIG. 2, ONOO - was abruptly induced by SIN-1, but the treatment group treated with SIN-1 and suthiazaponin (50 μM) ONOO - production was markedly inhibited, and ONOO - production was more remarkably inhibited than that of vitamin C (100 .mu.M), which is a positive control group (FIG. 2).
따라서, 스워티아자포닌은 강력한 ONOO- 소거능이 있는 것으로 알려진 비타민 C 보다도 더 우수한 ONOO- 소거능이 있음을 확인하여, 항산화 물질로 유용하게 사용될 수 있음을 재확인하였다.Therefore, it was confirmed that sulthiazaponin has an ONOO - eliminating ability superior to vitamin C, which is known to have a strong ONOO - eliminating ability, and thus it can be used effectively as an antioxidant.
실시예2Example 2 : : 스워티아자포닌의Of suotiazaponin 주름 개선 효과 확인 Check wrinkle improvement effect
2-1. 2-1. 스워티아자포닌의Of suotiazaponin 엘라스타제Elastase (( elastaseelastase ) 저해 효과 확인) Identification of inhibitory effect
스워티아자포닌의 주름 개선 효과는 다음과 같은 엘라스타제 저해 활성 측정으로 평가하였다. 구체적으로, 0.2M Tris-Cl 용액(pH 8.0)를 이용하여 스워티아자포닌을 최종농도가 1, 5, 10, 40 및 80μM 농도로 되도록 메탄올에 희석하여 준비하였다. 또한, 50mM Tris-Cl 용액(pH 8.6) 1ml에 엘라스타제(elastase) 기질인 N-숙시닐-(Ala)3-ρ-나이트로아닐라이드(N-succinyl-(Ala)3-pnitroanilide) 50mM을 5㎕ 넣어 기질용액을 제조하였고, 50mM Tris-Cl 용액(pH 8.6)를 이용하여 돼지 췌장 엘라스타제(Porcine pancreatic elastase, PPE)를 0.6units/ml 농도로 희석하여 효소용액을 제조하여 준비하였다. 그 다음 상기 다양한 농도로 희석된 스워티아자포닌 100㎕에 기질용액 100㎕ 및 효소용액 50㎕를 넣고 혼합한 후 37℃에서 20분 동안 반응시켰다. 그 다음 상기 반응물을 ELISA 리더를 이용하여 410nm에서 흡광도를 측정한 후 하기 수학식 1를 이용하여 엘라스타제 활성 (%)을 산출하였다. 이때, 무첨가군은 스워티아자포닌 대신 메탄올을 사용하였고, 비교군으로는 아데노신(adenosine)을 50μM 농도로 사용하였다.The wrinkle-improving effect of sulthiazaponin was evaluated by measuring the inhibitory activity of elastase as follows. Specifically, sulthiazaponin was diluted with methanol to a final concentration of 1, 5, 10, 40 and 80 μM using 0.2 M Tris-Cl solution (pH 8.0). N-Succinyl- (Ala) 3-pnitroanilide (50 mM) was added to 1 ml of a 50 mM Tris-Cl solution (pH 8.6) Was prepared and the enzyme solution was prepared by diluting porcine pancreatic elastase (PPE) to a concentration of 0.6 units / ml using 50 mM Tris-Cl solution (pH 8.6) . Subsequently, 100 μl of the substrate solution and 50 μl of the enzyme solution were added to 100 μl of the sultiazaponin diluted to various concentrations, and the mixture was reacted at 37 ° C. for 20 minutes. Then, the absorbance of the reactant was measured at 410 nm using an ELISA reader, and the elastase activity (%) was calculated using the following equation (1). At this time, methanol was used instead of suotiazaponin, and adenosine (50 μM) was used as a comparative group.
[수학식 1][Equation 1]
엘라스타아제 저해 활성(%) = {1-(시료첨가구의 흡광도/무첨가구의 흡광도)} × 100Elastase inhibitory activity (%) = {1- (absorbance of sample added / absorbance of non-additive)} 100
실험 결과, 도 3에서 확인할 수 있는 바와 같이, 스워티아자포닌 투여군(SJ_1, SJ_5, SJ_10, SJ_40, SJ_80 및 SJ_80)은 대조군과 비교하여 농도의존적으로 엘라스타제의 활성이 감소함을 확인할 수 있었으며, 그 농도가 40μM 이상인 경우, 대조군과 유의적인 차이를 나타내는 것을 확인하였다 (도 3). 특히, 50 μM 이상의 농도로 처리할 경우 엘라스타제 활성을 무려 약 70% 까지 억제함을 확인하였다.As shown in FIG. 3, it was confirmed that the activity of sartiazaponin-treated group (SJ_1, SJ_5, SJ_10, SJ_40, SJ_80 and SJ_80) decreased in a concentration-dependent manner in comparison with the control group , And when the concentration was 40 μM or more, there was a significant difference from the control group (FIG. 3). In particular, it was confirmed that the treatment with a concentration of 50 μM or more suppressed the elastase activity by as much as about 70%.
따라서, 스워티아자포닌은 우수한 엘라스타제 저해 효과가 있음을 확인하여, 피부 주름 개선 용도로 유용하게 사용할 수 있음을 확인하였다.Therefore, it was confirmed that sulthiazaponin has an excellent inhibitory effect on elastase, and thus it was confirmed that it can be usefully used for improving the wrinkles of the skin.
2-2. 2-2. 스워티아자포닌의Of suotiazaponin 인공피부에서의 주름 저해 활성 Wrinkle-inhibiting activity in artificial skin
스워티아자포닌의 광노화에 따른 주름 저해활성을 인공피부(3D human skin)에서 평가하였다. 구체적으로, 스워티아자포닌을 최종농도가 10, 20μM 농도가 되도록 인공피부에 1시간 전 처리한 뒤 UVB를 50mJ/cm2 조사하였다. 그 다음 5% CO2, 37℃ 및 95% 이상의 습도를 유지한 배양기에서 2일 동안 배양시킨 후 인공피부를 잘라 4% 파라포름알데히드에서 고정하고 tissue processing 과정을 거쳐 파라핀 블록으로 제작하였다. 파라핀 블록은 5μm의 두께로 절단하여 슬라이드에 부착시킨 뒤 마손 삼색염색법(Masson Trichrome stain)으로 염색하였다. 조직염색을 통하여 푸른색으로 염색된 콜라겐 섬유(collagen fiber)를 통하여 주름 저해 활성을 평가 하였다.The anti-wrinkle activity of the sultiazaponin due to photoaging was evaluated in 3D human skin. Specifically, soutiazaponin was treated with artificial skin for 1 hour before the final concentration to a concentration of 10, 20 μM, and irradiated with 50 mJ / cm 2 of UVB. After incubation for 2 days in an incubator maintained at 5% CO 2 , 37 ° C and 95% humidity, the artificial skin was cut and fixed with 4% paraformaldehyde and processed into a paraffin block through tissue processing. The paraffin block was cut to a thickness of 5 μm and attached to the slide, followed by staining with Masson Trichrome stain. The wrinkle inhibiting activity was evaluated through blue stained collagen fiber through tissue staining.
실험 결과, 도 4에서 확인할 수 있는 바와 같이, 정상군과 비교하여 UVB를 조사한 경우, 콜라겐 섬유가 감소한 것을 확인할 수 있는 반면, 스워티아자포닌을 처리한 경우, 농도 의존적으로 콜라겐 섬유가 현저하게 증가한 것을 확인하였다 (도 4).As shown in FIG. 4, when UVB was irradiated in comparison with the normal group, it was confirmed that the collagen fiber decreased, whereas when treated with sultiazaponin, the collagen fibers increased significantly in a concentration-dependent manner (Fig. 4).
따라서, 스워티아자포닌은 인공피부에서도 광노화에 의한 주름 저해 효과가 우수함을 확인하여, 피부 주름 개선 용도로 유용하게 사용할 수 있음을 재확인하였다.Accordingly, it has been confirmed that sulthiazaponin has an excellent effect of inhibiting wrinkles due to photoaging even in artificial skin, and thus it has been confirmed that it can be usefully used for improving skin wrinkles.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all aspects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (7)
A cosmetic composition for improving skin wrinkles comprising swertiajaponin or a cosmetically acceptable salt thereof as an active ingredient.
The cosmetic composition according to claim 1, wherein the composition inhibits the activity inhibition of elastase, the inhibition of active oxygen production, or the production of nitric acid nitrate.
The composition according to any one of claims 1 and 2, wherein the composition is selected from the group consisting of a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, a flexible water, a latex, a makeup base, an essence, , Sunscreen creams, sun oil, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays Lt; RTI ID = 0.0 > cosmetic < / RTI > composition.
An external skin preparation for improving skin wrinkles comprising swertiajaponin or an acceptable salt thereof as an active ingredient.
A health functional food for improving skin wrinkles comprising swertia japonin or a pharmaceutically acceptable salt thereof as an active ingredient.
A pharmaceutical composition for improving or treating skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
A quasi-drug composition for improving skin wrinkles comprising swertiajaponin or a pharmaceutically acceptable salt thereof as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170114064A KR102022621B1 (en) | 2017-09-06 | 2017-09-06 | An anti-wrinkle activity composition comprising swertiajaponin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170114064A KR102022621B1 (en) | 2017-09-06 | 2017-09-06 | An anti-wrinkle activity composition comprising swertiajaponin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190027415A true KR20190027415A (en) | 2019-03-15 |
| KR102022621B1 KR102022621B1 (en) | 2019-09-19 |
Family
ID=65762719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170114064A KR102022621B1 (en) | 2017-09-06 | 2017-09-06 | An anti-wrinkle activity composition comprising swertiajaponin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102022621B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150019680A (en) * | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
-
2017
- 2017-09-06 KR KR1020170114064A patent/KR102022621B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150019680A (en) * | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102022621B1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2858961B2 (en) | Cosmetic or pharmaceutical composition containing mangiferin or its derivative as active ingredient in pure form or as plant extract | |
| KR101663946B1 (en) | Cosmetic composition containing an ginsenoside Rg3 reinforced extract of fermentative Ginseng flower(Panax ginseng C. A. Meyer) by Aureobasidium pullulans | |
| US20130183257A1 (en) | Compositions and methods for improving skin appearance | |
| KR102144568B1 (en) | Composition for skin conditioning comprising Morus alba L. extract | |
| KR101837446B1 (en) | Composition for improving skin wrinkle or skin moisturing comprising alpha-, beta-, gamma-mangostin or gartanin compound as effective component | |
| KR20180090122A (en) | Composition for skin improvement containing isosakuranetin | |
| KR102002627B1 (en) | A skin-whitening composition comprising spinosin | |
| KR101587077B1 (en) | Composition containing fermentated opuntia humifusa showing biological activity of skin | |
| KR102022621B1 (en) | An anti-wrinkle activity composition comprising swertiajaponin | |
| KR102002628B1 (en) | A skin-whitening composition comprising swertiajaponin | |
| US9730872B2 (en) | Method for improving skin conditions with veratric acid or acceptable salt thereof as an active ingredient | |
| KR102022620B1 (en) | Composition for improving skin wrinkle comprising spinosin | |
| KR20190050353A (en) | Composition including midodrine and its uses | |
| EP1009378A1 (en) | Use of the rhoeo discolor plant extracts in cosmetics and pharmaceutics, in particular in dermatology | |
| KR102623565B1 (en) | Composition for improving skin comprising β-pinene as active ingredient | |
| KR101526592B1 (en) | Anti-wrinkle composition | |
| JP5313524B2 (en) | Anti-inflammatory agent and anti-inflammatory skin external preparation | |
| KR20160112546A (en) | Composition for improving skin conditions comprising syringic acid | |
| KR102178889B1 (en) | Skin-whitening cosmetic composition containing Mannitol as a active ingredient | |
| KR20170080074A (en) | Composition for improving skin conditions comprising brassinolide | |
| KR101434446B1 (en) | Composition for External Application to the Skin Using an Extract of Dictyota dichotoma | |
| KR101656322B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising gardenoside | |
| KR20140029654A (en) | Cosmetics containing boswellic acid | |
| KR20200036730A (en) | A composition for promoting skin turnover and promoting melanin release | |
| KR20140058052A (en) | Cosmetics containing gomisin a and/or gomisin n |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |